Antiviral therapies.
Hallenberger
Sabine
S
Institute of Virology, Bayer HealthCare, 0405 Wuppertal, Germany. sabine.hallenberger.sh@bayer-ag.de
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D015658:HIV Infections / Q000188:drug therapy; D006509:Hepatitis B / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D051379:Mice; D009282:Naphthalenesulfonates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy*
C434758:3-hydroxy-2,2-dimethyl-N-(4(((5-(dimethylamino)-1-naphthyl)sulfonyl)amino)phenyl)propanamide; D019380:Anti-HIV Agents; D000998:Antiviral Agents; C464059:BAY 41-4109; D009282:Naphthalenesulfonates; D011725:Pyridines; D011743:Pyrimidines; D013449:Sulfonamides; D013844:Thiazoles; C453221:pritelivir